← All comparisons
Head-to-head · FAERS comparison

Baclofen vs Meloxicam: side effects in FDA adverse event reports

Baclofen profile · Meloxicam profile · data 2026-09-14
How to read this page. FAERS report counts have no denominator; the comparison is of reporting patterns, not of risk. Signals are screened against each FDA label (badges) but not causally assessed. Not medical advice.

At a glance

BaclofenMeloxicam
Drug classgamma-Aminobutyric Acid-ergic AgonistNonsteroidal Anti-inflammatory Drug
Brand names––
FAERS reports85,58457,729
Serious67%58%
Death outcome6,4583,732
Boxed warningNoYes RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS See full prescribing information

Signals both drugs share

No strong shared signal after removing coding and lab terms.

Labeled signals distinctive to Baclofen

  • None stood out among the strongest labeled signals.

Labeled signals distinctive to Meloxicam

Common questions

Which has more reported side effects, Baclofen or Meloxicam?

Baclofen has 85,584 FAERS reports and Meloxicam 57,729. More reports does not mean more dangerous: volume follows how widely and how long a drug has been used, prescription vs over-the-counter status, and publicity. The seriousness share (67% vs 58%) is a better like-for-like signal of the kind of problems reported.

Which side effects do Baclofen and Meloxicam share?

They share no strong flagged signal after artifacts and lab terms are removed.

Is Baclofen or Meloxicam safer?

FAERS cannot answer that: it has no denominator and no comparator. Use this page to see which risks are already on each label and which signals are unlabeled, then check the prescribing information and your clinician for your situation.

Sources: openFDA FAERS pair statistics (OpenPV build 2026-09-14), FDA labels via openFDA, openFDA count queries for seriousness and deaths. Pair chosen because it is a commonly searched comparison. Generated 2026-10-08.